---
title: "Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290206255.md"
description: "Immix Biopharma's 12-month average price target was raised to $19.79 by seven analysts, up from $18.58. This implies an 117% upside based on the June 17 closing price. The consensus rating remains 'Buy' across all six covering analysts, with no holds or sells."
datetime: "2026-06-18T13:20:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290206255.md)
  - [en](https://longbridge.com/en/news/290206255.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290206255.md)
generator: "portal-rs"
---

# Immix Biopharma, Inc. Stock 12‑Month Price Target Raised to $19.79, Implies 117% Upside

-   According to estimates from 7 analysts, Immix Biopharma, Inc. stock's average price target has risen from $18.58 to $19.79, with forecasts ranging from $14.5 to $27 per share
-   Based on the Jun. 17 closing price, the updated target implies approximately 117% potential upside
-   Consensus rating remains at “Buy” across 6 covering analysts, with 6 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Immix Biopharma, Inc. on the , and track all previous and future analyst recommendations for Immix Biopharma, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [IMMX.US](https://longbridge.com/en/quote/IMMX.US.md)

## Related News & Research

- [Immix Biopharma highlights NXC-201 CAR-T data in relapsed/refractory AL amyloidosis trial presentation](https://longbridge.com/en/news/297810101.md)
- [Velan Capital Investment Management LP Has $11.19 Million Stock Holdings in Immix Biopharma, Inc. $IMMX](https://longbridge.com/en/news/297768757.md)
- [Baird Just Upgraded Deere Stock. Here's Why.](https://longbridge.com/en/news/297677018.md)
- [TenX Protocols Inc. reports Q1 results](https://longbridge.com/en/news/297560433.md)
- [Mundoro Capital Inc. GAAP EPS of $0.00](https://longbridge.com/en/news/297553342.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**